Followers | 324 |
Posts | 64,413 |
Boards Moderated | 3 |
Alias Born | 05/06/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NTRB Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
$NTRB The company operates in the health supplement market. Its product line consists of an Energy Patch line; a Weight Management supplement patch line; and a Multivitamin Patch line. The company offers its products through its Website. Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
NTRB may be just an opportunity for less risk-averse investors and traders. And, by contrast to our first name above, this is quite possibly a very early stage if the trend persists.
The company operates in the health supplement market. Its product line consists of an Energy Patch line; a Weight Management supplement patch line; and a Multivitamin Patch line. The company offers its products through its Website. Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
NTRB may be just an opportunity for less risk-averse investors and traders. And, by contrast to our first name above, this is quite possibly a very early stage if the trend persists.
The company operates in the health supplement market. Its product line consists of an Energy Patch line; a Weight Management supplement patch line; and a Multivitamin Patch line. The company offers its products through its Website. Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
NUTRIBAND ORD (OTCMKTS:NTRB) is clearly the more speculative play of the group here. But that is also the area of the market that tends to offer up the biggest home-run potential when these types of stocks work out. NTRB may be just an opportunity for less risk-averse investors and traders. And, by contrast to our first name above, this is quite possibly a very early stage if the trend persists.
The company operates in the health supplement market. Its product line consists of an Energy Patch line; a Weight Management supplement patch line; and a Multivitamin Patch line. The company offers its products through its Website. Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
NUTRIBAND ORD (OTCMKTS:NTRB) is clearly the more speculative play of the group here. But that is also the area of the market that tends to offer up the biggest home-run potential when these types of stocks work out. NTRB may be just an opportunity for less risk-averse investors and traders. And, by contrast to our first name above, this is quite possibly a very early stage if the trend persists.
The company operates in the health supplement market. Its product line consists of an Energy Patch line; a Weight Management supplement patch line; and a Multivitamin Patch line. The company offers its products through its Website. Nutriband Inc. was incorporated in 2016 and is based in Oviedo, Florida.
According to company materials, “Nutriband is a unique, result’s driven, health and pharmaceutical Company based in Orlando Florida. Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.“
Quite simply, for those in this stock from earlier this year, NTRB has been a huge trading profits machine, with shares rising by more than 300% over the past few months. But, critically, volume has remained very constrained, which suggests the stock could possibly have much more upside ahead if the crowd discovers it in a big way.
One big point in its favor is the extremely tight float – sitting at just a tiny 2.3 million shares. That can cause, effectively, a supply shock squeeze if we see some traction build in the name in terms of trader popularity, buzz, or attention.
This is key when one notes that the stock has recently been uplisted to the higher tier exchange on the OTC, granting it access to more institutional investors and a wider audience.
Crispr Therapeutics AG (NASDAQ:CRSP), a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis.
It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
This stock exploded higher at the end of 2017 and into this year. Shares blasted as much as 250% over the past 6 months, but have been consolidating a bit in recent action. With the gene-editing theme continuing to grip the imagination of the bigger dinosaurs in the pharma space, another run in front of some potential bids is not hard to imagine.
However, this is not what one might call an early-stage trend.
Crispr Therapeutics AG (NASDAQ:CRSP), a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis.
It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
This stock exploded higher at the end of 2017 and into this year. Shares blasted as much as 250% over the past 6 months, but have been consolidating a bit in recent action. With the gene-editing theme continuing to grip the imagination of the bigger dinosaurs in the pharma space, another run in front of some potential bids is not hard to imagine.
However, this is not what one might call an early-stage trend.
ANDI On power hour watch
ANDI on power hour watch
ANDI purchase orders, acquisitions, and more.
ANDI purchase orders, acquisitions, and more.
ANDI Above avg Volume alert
ANDI Above avg Volume alert
ANDI Over 120 mil in volume
ANDI over 120 mil in volume
Power hour should be exciting
ANDI
120 mil shares traded
ANDI
CRWG on watch after,bullish reaction,to,news
CRWG on watch after,bullish reaction,to,news
$CRWG seeks to expand their Cannabis digital holdings beyond http://WeedTracker.com
$CRWG seeks to expand their Cannabis digital holdings beyond http://WeedTracker.com
CRWG Cannabis stock with recent news.
CRWG Cannabis stock with recent news.
CRWG Cannabis sector is bullish
CRWG support is holding the line
CRWG support is holding the line
CRWG CrowdGather Provides Shareholder Update
https://finance.yahoo.com/news/crowdgather-provides-shareholder-093000289.html
CRWG CrowdGather Provides Shareholder Update
https://finance.yahoo.com/news/crowdgather-provides-shareholder-093000289.html
$ANDI Is 150 million volume,possible today?
$ANDI. Is 150 Million in volume possible today?
CRWG update this morning, now trading positive.
CRWG update this morning, now trading positive.
ANDI acquisition has helped add 30% gains today